Moderate to severe plaque psoriasis is in the spotlight of large pharmaceutical laboratories that propose dermatologists around the world new increasingly effective drugs, launched at a sustained pace. This article briefly presents the clinical trials that allowed the approval of the new molecules authorized in France and most European Community countries in the last 12 months: anti-interleukin 17A (IL-17A) secukinumab and ixekizumab and anti-phosphodiesterase-4 (PDE-4) apremilast - the first new oral treatment approved. The educational objectives of this article are: 1. a synthetic update to inform dermatologists about the efficacy and tolerance profile of the 3 new drugs against moderate to severe psoriasis in case of therapeutic failure or contraindication to 2 classical treatments; 2. to provide dermatologists with simplified information to prescribe a new systemic therapy well adapted to the profile of each patient with moderately to severe plaque psoriasis.